🚀 VC round data is live in beta, check it out!
Haemonetics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Haemonetics and similar public comparables like Integer Holdings, Autobio Diagnostics, Mehow Innovative, Dentsply Sirona and more.
Haemonetics Overview
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Founded
1971
HQ
Employees
3.0K
Website
Financials (LTM)
EV
$4B
Haemonetics Financials
Haemonetics reported last 12-month revenue of $1B and EBITDA of $417M.
In the same LTM period, Haemonetics generated $798M in gross profit, $417M in EBITDA, and $231M in net income.
Revenue (LTM)
Haemonetics P&L
In the most recent fiscal year, Haemonetics reported revenue of $1B and EBITDA of $417M.
Haemonetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $798M | XXX | $749M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $417M | XXX | $417M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $231M | XXX | $232M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $918M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Haemonetics Stock Performance
Haemonetics has current market cap of $3B, and enterprise value of $4B.
Market Cap Evolution
Haemonetics' stock price is $63.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $3B | 0.0% | XXX | XXX | XXX | $4.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHaemonetics Valuation Multiples
Haemonetics trades at 2.9x EV/Revenue multiple, and 9.2x EV/EBITDA.
EV / Revenue (LTM)
Haemonetics Financial Valuation Multiples
As of March 28, 2026, Haemonetics has market cap of $3B and EV of $4B.
Equity research analysts estimate Haemonetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haemonetics has a P/E ratio of 12.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.2x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBIT | 11.1x | XXX | 11.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 5.1x | XXX | XXX | XXX |
| P/E | 12.8x | XXX | 12.8x | XXX | XXX | XXX |
| EV/FCF | 21.4x | XXX | 26.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Haemonetics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Haemonetics Margins & Growth Rates
Haemonetics' revenue in the last 12 month grew by 5%.
Haemonetics' revenue per employee in the last FY averaged $0.4M.
Haemonetics' rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haemonetics' rule of X is 44% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Haemonetics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | (3%) | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Haemonetics Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Integer Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Autobio Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mehow Innovative | XXX | XXX | XXX | XXX | XXX | XXX |
| Dentsply Sirona | XXX | XXX | XXX | XXX | XXX | XXX |
| Double Medical Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haemonetics M&A Activity
Haemonetics acquired XXX companies to date.
Last acquisition by Haemonetics was on XXXXXXXX, XXXXX. Haemonetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Haemonetics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHaemonetics Investment Activity
Haemonetics invested in XXX companies to date.
Haemonetics made its latest investment on XXXXXXXX, XXXXX. Haemonetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Haemonetics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Haemonetics
| When was Haemonetics founded? | Haemonetics was founded in 1971. |
| Where is Haemonetics headquartered? | Haemonetics is headquartered in United States. |
| How many employees does Haemonetics have? | As of today, Haemonetics has over 3K employees. |
| Who is the CEO of Haemonetics? | Haemonetics' CEO is Christopher A. Simon. |
| Is Haemonetics publicly listed? | Yes, Haemonetics is a public company listed on NYSE. |
| What is the stock symbol of Haemonetics? | Haemonetics trades under HAE ticker. |
| When did Haemonetics go public? | Haemonetics went public in 1991. |
| Who are competitors of Haemonetics? | Haemonetics main competitors are Integer Holdings, Autobio Diagnostics, Mehow Innovative, Dentsply Sirona. |
| What is the current market cap of Haemonetics? | Haemonetics' current market cap is $3B. |
| What is the current revenue of Haemonetics? | Haemonetics' last 12 months revenue is $1B. |
| What is the current revenue growth of Haemonetics? | Haemonetics revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Haemonetics? | Current revenue multiple of Haemonetics is 2.9x. |
| Is Haemonetics profitable? | Yes, Haemonetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haemonetics? | Haemonetics' last 12 months EBITDA is $417M. |
| What is Haemonetics' EBITDA margin? | Haemonetics' last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Haemonetics? | Current EBITDA multiple of Haemonetics is 9.2x. |
| What is the current FCF of Haemonetics? | Haemonetics' last 12 months FCF is $179M. |
| What is Haemonetics' FCF margin? | Haemonetics' last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Haemonetics? | Current FCF multiple of Haemonetics is 21.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.